Saúde 24 Fevereiro 2026

Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
···

Por que as ações da SLS estão subindo no pré-mercado: SELLAS Life Sciences retoma a contagem regressiva do estudo REGAL de Fase 3

A SELLAS Life Sciences subiu 3,4% no pré-mercado nesta segunda, negociada a US$ 4,29 após fechar a US$ 4,15 na sexta-feira. O mercado acompanha de perto a divulgação dos resultados do estudo de Fase 3 em LMA, prevista para meados de março. O volume negociado na sexta foi de 5,9 milhões de ações, com forte interesse vendido.
Fevereiro 24, 2026

Stock Market Today

  • Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
    May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.